pyrroles has been researched along with Bladder Cancer in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.78) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 23 (63.89) | 24.3611 |
| 2020's | 8 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Breitbach, JT; Fenger, JM; Geisler, JA; Husbands, BD; Korec, DI; Louke, DS | 1 |
| Féliz, L; Gutierrez, M; Iannotti, NO; Ji, T; Lihou, CF; Saleh, M; Silverman, IM; Smith, DC; Subbiah, V; Tian, C | 1 |
| Hu, C; Hu, X; Wang, L; Zhao, Y | 1 |
| Hodgson-Garms, M; Ioannidis, P; Jenkins, LJ; Lau, DK; Lavis, A; Luk, IY; Mariadason, JM; Vukelic, N; Weickhardt, AJ | 1 |
| Bian, XJ; Cai, J; Chen, C; Han, W; He, C; Luo, H; Qu, YY; Sun, Z; Wang, Q; Xing, N; Ye, DW; Zhang, X; Zou, Q | 1 |
| Jeong, BC; Kim, H; Lee, IK; Lee, J; Lee, SJ; Min, SC; Park, SH; Sung, HH | 1 |
| Al-Obaidy, KI; Cheng, L | 1 |
| Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A | 1 |
| Aschelter, AM; Capriotti, G; Cerquetti, L; Lardo, P; Marchetti, P; Matarazzo, I; Nardone, MR; Petrangeli, E; Schiavi, F; Stigliano, A; Toscano, V | 1 |
| Ghosh, PM; Sam, A; Steele, TM; Talbott, GC; Tepper, CG; Vinall, RL | 1 |
| Amantini, C; Berardi, R; Bonfili, L; Burattini, L; Cascinu, S; Eleuteri, AM; Farfariello, V; Liberati, S; Morelli, MB; Mozzicafreddo, M; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F | 1 |
| Arantes-Rodrigues, R; Colaço, A; Fidalgo-Gonçalves, L; Oliveira, P; Palmeira, C; Pinto-Leite, R; Santos, L | 1 |
| Biddick, L; Kopelovich, L; Li, Q; Lightfoot, S; Madka, V; Mohammed, A; Patlolla, JM; Rao, CV; Steele, V; Wu, XR; Zhang, Y | 1 |
| Jeong, CW; Kang, M; Kim, HH; Ku, JH; Kwak, C | 1 |
| Ji, ZG; Jin, J; Li, HZ; Wen, J | 1 |
| Alwhaibi, A; Gao, F; Goc, A; Pruitt, A; Sabbineni, H; Somanath, PR | 1 |
| Chew, DJ; Drost, WT; Gardner, HL; Green, EM; Hostnik, ET; London, CA; Nguyen, SM; Peng, J; Portela, RA; Rippy, SB; Warry, EE | 1 |
| Azzoli, CG; Calcutt, MW; Janjigian, YY; Kris, MG; Krug, LM; Lee, W; Miller, VA; Rizvi, NA; Senturk, E | 1 |
| Bajorin, DF; Boyle, MG; Flaherty, AM; Gallagher, DJ; Gerst, SR; Ishill, N; Milowsky, MI; Regazzi, A; Riches, J; Trout, A | 1 |
| Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
| Ping, SY; Wu, CL; Yu, DS | 1 |
| Chester, JD; Cooper, PA; Knowles, MA; Lamont, FR; Shnyder, SD; Tomlinson, DC | 1 |
| Campbell, SC; Fergany, AF; Garcia, JA; Ghoneim, IA; Gong, MC; Hansel, DE; Miocinovic, R; Stephenson, AJ | 1 |
| Eto, M; Itsumi, M; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A | 1 |
| Ping, SY; Wu, CL; Yu, CP; Yu, DS | 1 |
| Chan, ES; Hansel, DE; Heston, WD; Larchian, WA; Patel, AR | 1 |
| Figueiredo, A; Mota, A; Neto, P; Parada, B; Pinto, Â; Reis, F; Rocha-Pereira, P; Sereno, J; Teixeira, F; Xavier-Cunha, M | 1 |
| Alandas, MN; Cooper, PA; Gill, JH; Illingworth, NA; Laye, JP; Loadman, PM; Patterson, LH; Pors, K; Searcey, M; Sheldrake, HM; Shnyder, SD; Sutherland, M | 1 |
| Asmar, L; Galsky, MD; Gardner, TA; Hahn, NM; Hellerstedt, BA; Hutson, TE; Kocs, D; Lerner, SP; McKenney, SA; Melnyk, AM; O'Rourke, M; Powles, T; Rauch, M; Sonpavde, G; Vogelzang, NJ; Wang, Y; Yu, M | 1 |
| Vogelzang, NJ | 1 |
| Bernard-Pierrot, I; Brams, A; Caillault, A; Cappellen, D; Chopin, D; Diez de Medina, SG; Dunois-Lardé, C; Graff, G; Radvanyi, F; Ricol, D; Thiery, JP | 1 |
| Kamat, AM; Nelkin, GM | 1 |
| Miroglu, C; Silay, MS | 1 |
| Bradley, DA; Dreicer, R; Dunn, R; Hussain, M; Nanus, D; Rosenberg, J; Smith, DC; Stadler, W | 1 |
| Morton, DM; Tchao, R | 1 |
2 review(s) available for pyrroles and Bladder Cancer
| Article | Year |
|---|---|
Fibroblast growth factor receptor (
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Exons; Gene Amplification; Gene Fusion; Genetic Predisposition to Disease; Humans; Molecular Targeted Therapy; Mutation, Missense; Phenotype; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms; Urothelium | 2021 |
Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2010 |
6 trial(s) available for pyrroles and Bladder Cancer
| Article | Year |
|---|---|
FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Cholangiocarcinoma; Female; Fibroblast Growth Factors; Humans; Lung Neoplasms; Male; Morpholines; Neoplasm Recurrence, Local; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2022 |
Camrelizumab plus famitinib for advanced or metastatic urothelial carcinoma after platinum-based therapy: data from a multicohort phase 2 study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Female; Humans; Indoles; Male; Platinum; Pyrroles; Urinary Bladder Neoplasms | 2022 |
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors.
Topics: Aged; Antineoplastic Agents; Benzodiazepinones; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Ovarian Neoplasms; Pyrroles; Urinary Bladder Neoplasms | 2010 |
Phase II study of sunitinib in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Indoles; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Pyrroles; Sunitinib; Survival Analysis; Urinary Bladder Neoplasms; Urothelium | 2010 |
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pyrroles; Sunitinib; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2013 |
Randomized, double-blind, placebo-controlled phase II trial of maintenance sunitinib versus placebo after chemotherapy for patients with advanced urothelial carcinoma: scientific rationale and study design.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Endpoint Determination; Humans; Indoles; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Research Design; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
28 other study(ies) available for pyrroles and Bladder Cancer
| Article | Year |
|---|---|
Characterization of receptor tyrosine kinase activation and biological activity of toceranib phosphate in canine urothelial carcinoma cell lines.
Topics: Animals; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Dog Diseases; Dogs; Female; Indoles; Male; Pyrroles; Receptor Protein-Tyrosine Kinases; Urinary Bladder Neoplasms | 2021 |
Novel smac mimetic ASTX660 (Tolinapant) and TNF-α synergistically induce necroptosis in bladder cancer cells in vitro upon apoptosis inhibition.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Caspases; Female; Humans; Male; Morpholines; Necroptosis; Necrosis; Piperazines; Pyrroles; Receptor-Interacting Protein Serine-Threonine Kinases; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms | 2022 |
Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.
Topics: Cell Line, Tumor; Female; Humans; Male; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Receptor, ErbB-3; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2022 |
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Imidazoles; Inhibitory Concentration 50; Morpholines; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2020 |
FGFR alterations in urothelial carcinoma: Picking the right target.
Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms | 2021 |
Treatment responses to antiangiogenetic therapy and chemotherapy in nonsecreting paraganglioma (PGL4) of urinary bladder with SDHB mutation: A case report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Indoles; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Paraganglioma; Pyrroles; Succinate Dehydrogenase; Sunitinib; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2018 |
Obatoclax, a BH3 Mimetic, Enhances Cisplatin-Induced Apoptosis and Decreases the Clonogenicity of Muscle Invasive Bladder Cancer Cells via Mechanisms That Involve the Inhibition of Pro-Survival Molecules as Well as Cell Cycle Regulators.
Topics: bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cyclin D1; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Invasiveness; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Necrosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reactive Oxygen Species; Sulfonamides; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
Topics: Animals; Biglycan; Gene Expression Regulation, Neoplastic; Humans; Indoles; Leucine; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyrroles; RNA, Messenger; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Synergistic effect between cisplatin and sunitinib malate on human urinary bladder-cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Humans; Indoles; Pyrroles; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Chemoprevention of urothelial cell carcinoma growth and invasion by the dual COX-LOX inhibitor licofelone in UPII-SV40T transgenic mice.
Topics: Animals; Antigens, Polyomavirus Transforming; Blotting, Western; Carcinoma in Situ; Cell Movement; Cell Proliferation; Female; Immunoenzyme Techniques; Lipoxygenase; Male; Mice; Mice, Transgenic; Neoplasm Invasiveness; Promoter Regions, Genetic; Prostaglandin-Endoperoxide Synthases; Pyrroles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms; Uroplakin II | 2014 |
Inhibition of autophagy potentiates atorvastatin-induced apoptotic cell death in human bladder cancer cells in vitro.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Apoptosis; Atorvastatin; Autophagy; Cell Line, Tumor; Heptanoic Acids; Humans; Pyrroles; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Effects of sunitinib malate on growth of human bladder transitional cell line T24 in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Fas Ligand Protein; fas Receptor; Humans; In Vitro Techniques; Indoles; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Urinary Bladder Neoplasms; Wound Healing | 2015 |
Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.
Topics: Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Nucleus; Cell Proliferation; Cytoplasm; Gene Knockdown Techniques; Humans; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; RNA, Small Interfering; Urinary Bladder Neoplasms | 2015 |
A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Dog Diseases; Dogs; Female; Indoles; Male; Pilot Projects; Pyrroles; Reproducibility of Results; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; BCG Vaccine; Bcl-2-Like Protein 11; bcl-X Protein; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Membrane Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
Topics: Animals; Apoptosis; Benzimidazoles; Blotting, Western; Carcinoma, Transitional Cell; Cell Cycle; Cell Proliferation; Cells, Cultured; Humans; Immunoenzyme Techniques; In Vitro Techniques; Male; Mice; Mice, Inbred BALB C; Mutation; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2011 |
Neoadjuvant systemic therapy or early cystectomy? Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cystectomy; Female; Humans; Indoles; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pyrroles; Retrospective Studies; Sunitinib; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Sunitinib enhances antitumor effects against chemotherapy-resistant bladder cancer through suppression of ERK1/2 phosphorylation.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C3H; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Kinase Inhibitors; Pyrroles; Signal Transduction; Sunitinib; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Time Factors; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Tyrosine kinase receptor inhibitor-targeted combined chemotherapy for metastatic bladder cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Epirubicin; Female; Humans; Indoles; Mice; Neoplasm Metastasis; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Humans; Indoles; Mice; Mice, Inbred C3H; Neoplasm Invasiveness; Pyrroles; Sunitinib; Urinary Bladder Neoplasms | 2012 |
Chemopreventive efficacy of Atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties.
Topics: Animals; Anti-Inflammatory Agents; Anticarcinogenic Agents; Antioxidants; Atorvastatin; Biomarkers, Tumor; Butylhydroxybutylnitrosamine; Cell Proliferation; Drug Evaluation, Preclinical; Heptanoic Acids; Male; Oxidative Stress; Pyrroles; Rats, Wistar; Urinary Bladder; Urinary Bladder Neoplasms | 2012 |
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder.
Topics: Animals; Antineoplastic Agents; Biotransformation; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cytochrome P-450 CYP1A1; Female; Gene Expression; Humans; Indoles; Liver; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Microsomes, Liver; Pyrroles; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.
Topics: Animals; Cell Transformation, Neoplastic; DNA Mutational Analysis; Epithelial Cells; Female; Fibroblasts; Humans; Mice; Mice, Nude; Protein Isoforms; Pyrroles; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection; Transplantation, Heterologous; Urinary Bladder Neoplasms | 2006 |
Atorvastatin: a potential chemopreventive agent in bladder cancer.
Topics: Atorvastatin; Carcinoma, Transitional Cell; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrroles; Urinary Bladder Neoplasms | 2005 |
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2007 |
Regulation of motility and cytoskeletal organization of rat bladder carcinoma cells by cyclic AMP.
Topics: Actinin; Actins; Animals; Bucladesine; Carbazoles; Cell Membrane; Cell Movement; Cholera Toxin; Cyclic AMP; Cytoskeleton; Indoles; Protein Kinase Inhibitors; Protein Kinases; Pyrroles; Rats; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Virulence Factors, Bordetella | 1994 |